March 2, 2017 / 9:34 PM / 7 months ago

BRIEF-Scynexis delays initiation of new clinical studies

March 2 (Reuters) - Scynexis Inc:

* Scynexis delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request

* Scynexis Inc says ongoing and future trials using oral formulation of SCY-078 are unaffected by this regulatory action

* Scynexis -meeting with FDA to discuss these data and to agree on subsequent clinical studies with iv formulation of SCY-078 is scheduled for Q2 of 2017

* Scynexis -FDA has informed company to hold initiation of any new clinical studies with intravenous (IV) formulation of SCY-078 until FDA completes review Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below